BTK Inhibitors
Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
MERCK SHARP & DOHME CORP. MERCK SHARP & DOHME B.V.
A A A A C A A A A A C A A A C A A C A A A A A A A A A A A A A A A A A A A A A A
A61P A61P A61P A61P C07D A61P A61P A61P A61P A61P C07D A61P A61P A61P C07D A61P A61P C07D A61P A61P A61P A61P A61P A61K A61P A61P A61P A61K A61K A61K A61P A61P A61P A61P A61P A61P A61P A61K A61P A61K
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Younong Arthur A. Shilan Allard Hao Xiaolei Alan B. Henry M. Chundao Ronald M. Hans C. A. Sobhana Babu Hugh Y. Abdul-Basit Johannes Bernardus Maria Jacobus C. H. M. Rajan Jan-Gerard Christiaan Gerardus Johannes Maria Xin Adrianus Petrus Antonius James Tjeerd A. Jian
Yu Oubrie Liu Kaptein Wu Gao Cooper Vaccaro Yang Kim Raaijmakers Boga Zhu Alhassan Rewinkel Wijkmans Anand Sterrenburg Jans Yao De Man Wang Barf Liu